CFLAR and neoplasm: As the activity of TRAIL is prevented by c-FLIP overexpression, targeting c-FLIP using our new molecules may restore TRAIL function, as it is broadly referenced in several studies showing that c-FLIP silencing sensitizes tumor cells to death ligand-induced apoptosis [51].